Piramal Pharma Limited (PPLPHARMA) Gross Profit 2022–2026

Name: Piramal Pharma Limited (PPLPHARMA) gross profit history 2022-2026
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-09-20

Piramal Pharma Limited annual gross profit for fiscal 2026 was ₹51.8 billion, a decrease of 5.7% from ₹54.9 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

PPLPHARMA Annual Gross Profit

Gross Profit (annual)	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Gross Profit	₹51.8B	₹54.9B	₹48.5B	₹40.3B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PPLPHARMA Quarterly Gross Profit

Gross Profit (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-06-30	2025-03-31
Gross Profit	₹14.2B	₹17.0B	₹13.5B	₹12.4B	₹18.0B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Gross Profit at Comparable Companies

WOCKPHARMA Gross Profit — Wockhardt Limited
1276 Gross Profit — Jiangsu Hengrui Pharmaceuticals Co.,Ltd
NEULANDLAB Gross Profit — Neuland Laboratories Limited
4540 Gross Profit — Tsumura & Co.
4516 Gross Profit — Nippon Shinyaku Co., Ltd.
3692 Gross Profit — Hansoh Pharmaceutical Group Company Limited

More PPLPHARMA metrics: Revenue · Operating Income · Net Income · EPS · Free Cash Flow

All PPLPHARMA financial statements → Interactive PPLPHARMA charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.